webcast resource

When is an assay “ready” for the clinic with regard to quality management from the health care perspective? Who decides this, and what information do they use to decide?

QA & QC from pre analytical steps to clinical utility

September 08, 2016 | Length: 21:30 min


Congress:Innovation and Biomarkers in Cancer Drug Development
Presenter:E. Schneider

Dr. Erasmus Schneider joined the Wadsworth Center in 1995 when he established an externally funded research program in multidrug resistance of cancer cells, including against drugs that target the folate pathway and DNA precursor synthesis. This work resulted in numerous peer-reviewed publications and presentations at major conferences. He reviewed grants for the American Cancer Society and is a member of its Council for Extramural Research. Before assuming his current role as the Wadsworth Center’s Associate Director for Research and Technology Dr. Schneider was the director of its Division of Translational Medicine. He is also the director of the Oncology section in New York State’s Clinical Laboratory Reference System. He is responsible for the review of laboratory-developed tests in the area of Oncology, and for conducting proficiency testing for serum tumor markers, human papilloma virus, molecular oncology and fetal defect markers. He is particularly interested in the technical and quality control challenges posed by the advanced molecular techniques used for the diagnosis, prognosis and prediction of therapeutic response of cancer.

Category: Cancer;